AVT29 (proposed aflibercept HD biosimilar) + Eylea HD (aflibercept HD)

Phase 3Recruiting

0 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Macular Edema

Conditions

Diabetic Macular Edema

Trial Timeline

Mar 1, 2026 → Jan 1, 2028

NCT ID

NCT07489131

About AVT29 (proposed aflibercept HD biosimilar) + Eylea HD (aflibercept HD)

AVT29 (proposed aflibercept HD biosimilar) + Eylea HD (aflibercept HD) is a phase 3 stage product being developed by Alvotech for Diabetic Macular Edema. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07489131. Target conditions include Diabetic Macular Edema.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Macular Edema were approved

Approved (20) Terminated (3) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07489131	Phase 3	Recruiting	Mar 1, 2026	Jan 1, 2028	Diabetic Macular Edema

Competing Products

20 competing products in Diabetic Macular Edema

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	44
CHF6467 active	Comac Medical	Phase 1/2	33
Ruboxistaurin mesylate	Eli Lilly	Phase 3	77
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	47
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	28
Baricitinib + Placebo	Eli Lilly	Phase 2	52
LY3857210 + Placebo	Eli Lilly	Phase 2	52
UBX1325	Unity Biotechnology	Phase 2	44
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	44
UBX1325	Unity Biotechnology	Phase 1	25
CT-P42 + Eylea	Celltrion	Phase 3	77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	85
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	85
CS-3150 + placebo	Daiichi Sankyo	Phase 2	52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	52
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	77
DS-5565 + placebo	Daiichi Sankyo	Phase 3	77
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	77
DS-5565	Daiichi Sankyo	Phase 3	77
Beraprost sodium	Astellas Pharma	Pre-clinical	23